About Merck & Co.
Merck & Co., known as MSD (Merck Sharp & Dohme) outside the United States and Canada, is a global pharmaceutical company that discovers, develops, and manufactures vaccines, medicines, and animal health products.
Our Legacy
Founded in 1891 in New York, Merck has a long history of medical breakthroughs including the first synthetic vitamin B1, the first statin (Mevacor), and more recently the groundbreaking immunotherapy Keytruda (pembrolizumab).
Key Products
Keytruda is one of the best-selling drugs in the world, approved for over 30 cancer indications. Merck's portfolio also includes Gardasil (HPV vaccine), Januvia (diabetes), and Lagevrio (COVID-19 treatment). The company's animal health division MSD Animal Health is a global leader.
Research Pipeline
Merck invests over $12 billion annually in R&D, with a pipeline focused on oncology, vaccines, infectious diseases, and cardiometabolic disorders. The company is advancing next-generation immunotherapies and combination treatments.
Global Reach
Headquartered in Rahway, New Jersey, Merck employs over 72,000 people and operates in 140 countries. The company reported $60.1 billion in revenue in 2023, with Keytruda alone contributing over $25 billion.
Leadership
Robert M. Davis has served as Chairman and CEO since 2022. Under his leadership, Merck continues to expand its oncology franchise and advance its pipeline through strategic acquisitions.